Astrazeneca Pharma India Ltd vs Sai Life Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8233 as of 05 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Sai Life Sciences Ltd changed from 93.4 on March 2025 to 93.4 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Sai Life Sciences Ltd changed from ₹ 15883 crore on March 2025 to ₹ 15883 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sai Life Sciences Ltd for the Dec '25 is ₹ 564.84 crore as compare to the Sep '25 revenue of ₹ 552.8 crore. This represent the growth of 2.18% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sai Life Sciences Ltd for the Dec '25 is ₹ 187.94 crore as compare to the Sep '25 ebitda of ₹ 161.15 crore. This represent the growth of 16.62% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Sai Life Sciences Ltd changed from ₹ -13.5 crore to ₹ 100.38 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Sai Life Sciences Ltd changed from 443.82 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Sai Life Sciences Ltd

Sai Life Sciences Limited was originally incorporated as Sai Dru Syn Laboratories Limited' as a Public Limited Company, dated January 25, 1999, issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.
The Company received the Certificate of Commencement of Business from Registrar of Companies, Andhra Pradesh on February 17, 1999.
Subsequently, the Company name was changed from Sai Dru Syn Laboratories Limited' to Sai Life Sciences Limited' dated December 16, 2003. Thereafter, the name of the Company was changed from Sai Life Sciences Limited' to Sai Advantium Pharma Limited' dated August 30, 2006 issued by the Registrar of Companies, Andhra Pradesh.
Subsequently, the Company name was changed from Sai Advantium Pharma Limited' to Sai Life Sciences Limited' and a fresh Certificate of Incorporation dated May 28, 2012 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Sai Life Sciences Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Sai Life Sciences Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,116 Cr while Market cap of Sai Life Sciences Ltd is 22,929 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Sai Life Sciences Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Sai Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Sai Life Sciences Ltd?

As of May 5, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8046.55. On the other hand, Sai Life Sciences Ltd stock price is INR ₹1082.7.

How do dividend payouts of Astrazeneca Pharma India Ltd and Sai Life Sciences Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Sai Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.